Implementing Diverse Mechanisms of Action Across Improved Clinical Translation to Develop Safe, Effective & Deliverable Next Generation Therapeutics for Glioblastoma Patients
Together we will increase the length and quality of patient survival from diagnosis.
The 3rd Glioblastoma Drug Development Summit is the only industry led forum for large pharma, biotech and academic KOLs to unite under the common goal of accelerating the practical translation and clinical development of meaningful therapies for the treatment of glioblastoma.
Through investigating the clinical implementation of diverse mechanisms of action, including, DNA damage repair, immunotherapy, oncolytic viruses, cholesterol metabolism, PARP inhibitors and more, we strive to address the urgent need for novel and much improved treatments for this devastating disease.
Tackling specific drug development challenges such as a better understanding of preclinical efficacy and tolerability data to confidently translate into the clinic, improving drug delivery across the blood-brain barrier and optimizing clinical trial design to define more measurable outcomes, this meeting is an absolute must attend for all neuro-oncologists and oncology professionals determined to translate their drug candidates into human clinical trials.
With a huge unmet medical need for effective treatments and too many clinical failures to overcome, there has never been a more important time to attend the 3rd Glioblastoma Drug Development Summit and join your dedicated and determined community to defeat GBM and radically change patients’ lives.
Join us as we unite drug developers and academics to tackle unique drug development challenges creating obstacles for effective treatments for GBM patients
30+ Expert Speakers Include:
Who Attended in 2020?
Hear From Our Attendees Last Year...
“It was a great meeting filled with very impactful presentation and discussions”
Director & Bioscience Leader, AstraZeneca
“Excellent presentations, candid atmosphere, very high-quality materials”
Chief Executive Officer, ExoProTher Medical
“The quality and relevancy of the content and the representative leadership was bar none”
Chief Business Officer, Global Coalition for Adaptive Research
“This was a highly well-organized, engaging and unique for this type of conference as it was science driven with excellent speakers and panel members”
Senior Director, Inovio Pharmaceuticals
“GBM DDS is the definitive meeting on GBM and an excellent opportunity to understand the length and breadth of drug development activity in this disease”
Chief Executive Officer, Kazia Therapeutics